Fibromyalgia Care Breakthrough: DEA Green Lights Biotech Partnership Exploring Ketamine Implant Therapy
Silo Pharma’s (NASDAQ: SILO) novel ketamine-loaded implant targeting fibromyalgia and chronic pain conditions, SP-26, is reportedly ad
Pete Davidson Reveals He’s Tried Ketamine To Cope With Depression
News of psychedelics and who is using them keeps making headlines.
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic.
PharmaTher’s Novel Ketamine Heads For The US Market With New Collaboration Agreement
Psychedelics biotech PharmaTher Holdings (OTCQB: PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary racemic ketamine products, KETARX, in the U.S. market.
Braxia Scientific’s Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
Research and telemedicine company Braxia Scientific Corp. (OTC: BRAXF) has filed its financial statements for the third quarter ended Dec.
Two New Studies On Classical Psychedelics: Grading Ketamine’s Components, Tuning Down Psilocybin Dosing
Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect
Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee.
New, Standardized Magic Mushroom Microdosing Capsules By Red Light Holland And Partner CCrest Labs
atai Life Sciences’ Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
Clinical-stage psychedelics biotech atai Life Sciences (NASDAQ: ATAI) shared the results of its NYC-based subsidiary NYC-based Perception Neuroscience’s Phase 2a study of proprietary R-ketamine PCN-101 on patients with Treatment-Resistant Depression (TRD.).
Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022.
Financials showed:
Ketamine Therapy: Revitalist’s New Financing Option, Irwin Naturals Expands Chain Of Clinics
Revitalist Increases Patient Access By Financing Costs With M-Lend Financial